

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :  C07K 14/435, C12N 1/20, 15/63, 21/04, C12P 21/06		A1	(11) International Publication Number: <b>WO 98/22502</b>
			(43) International Publication Date: 28 May 1998 (28.05.98)
(21) International Application Number: PCT/US97/21517  (22) International Filing Date: 24 November 1997 (24.11.97)			(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(30) Priority Data: 08/755,559 22 November 1996 (22.11.96) US			Published <i>With international search report.</i>
(71) Applicant: DUKE UNIVERSITY [US/US]; 230 North Building, Research Drive, Box 90083, Durham, NC 27708-0083 (US).			
(72) Inventors: KAUFMAN, Russel, E.; 3902 Hope Valley Road, Durham, NC 27707 (US). SLENTZ-KESLER, Kimberly, A.; Duke University, Carl Building, Room 226, Durham, NC 27710 (US).			
(74) Agent: WILSON, Mary, J.; Nixon & Vanderhye P.C., 8th floor, 1100 North Glebe Road, Arlington, VA 22201-4714 (US).			

(54) Title: GENE PRODUCT OVER EXPRESSED IN CANCER CELLS

## (57) Abstract

The present invention relates, in general, to a cancer-related protein and to a nucleic acid sequence encoding same. In particular, the invention relates to a protein over expressed in certain neoplastic cells, including breast and ovarian cancer cells, to its encoding sequence, and to diagnostic and treatment methodologies based on same.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## GENE PRODUCT OVER EXPRESSED IN CANCER CELLS

The present invention relates, in general, to a cancer-related protein and to a nucleic acid sequence encoding same. In particular, the invention relates 5 to a protein over expressed in certain neoplastic cells, including breast and ovarian cancer cells, to its encoding sequence, and to diagnostic and treatment methodologies based on same.

BACKGROUND

10       Breast cancer represents the most frequent cause of early morbidity and mortality in women in North America (Harris et al, New Eng. J. Med. 327:319, 390 and 473 (1992)). It is generally believed that this malignancy arises from a multi step process involving 15 mutations in a relatively small number of genes, perhaps 10 or less. These mutations result in significant changes in the growth and differentiation of breast tissue that allow it to grow independent of normal cellular controls, to metastasize, and to 20 escape immune surveillance. The genetic heterogeneity of most breast cancers suggests that they arise by a variety of initiating events and that the characteristics of individual cancers are due to the collective pattern of genetic changes that 25 accumulate (Harris et al, New Eng. J. Med. 327:319, 390 and 473 (1992)).

The classes of genes that are involved in breast cancer are not unlike those found in a number of other well characterized malignancies, although some are highly specific for breast cancer. In 5 particular, mutations in the genes that encode receptors involved in binding to estrogen and progesterone are particularly important because they likely cause the breast cells to proliferate while rendering them unresponsive to the antitumor effects 10 of these hormones in advanced malignancy. In addition, changes in the genes that encode growth factors, other receptors, signal transduction molecules, and transcription factor molecules are frequently involved and have alterations that are 15 involved in the development and progression of breast cancer (King, *Nature Genetics* 2:125 (1992)). The characterization of the type and number of mutations seen in individual breast cancers is useful in classifying the biological properties of individual 20 cancers and in determining the prognosis for individual patients. For example, the erbB2/HER2/neu gene is particularly valuable in predicting the prognosis of both node-positive and node-negative patients based on the amplification status of the 25 gene (King, *Science* 250:1684 (1990)). Several additional members of this family have been discovered but the ligand for erbB2/HER2/neu remains unknown. It is anticipated that further advances in therapeutics will be achieved by the development of 30 therapies that disrupt aberrant growth signaling pathways or affect the cellular interactions of

breast cancer cells with native stroma or metastatic sites.

5       Although oncogenes are likely to be very important in breast cancer, tumor suppressor genes may also play an important role. Certain of these genes, including p53 and Rb-1, are essential to the normal mechanisms that control cell cycle events, especially those checkpoints at the border of the different stages of the cell cycle (Hollstein et al, 10      Science 253:49 (1991); Srivastava et al, Nature 348:747 (1990)).

15      In 1969, Li and Fraumeni documented a familial cancer syndrome that had an autosomal dominant pattern of expression (Li et al, Ann. Intern. Med. 71:747 (1969)). Members of these families had sarcomas, breast cancers, brain tumors, leukemias, adrenocortical carcinomas, and other malignancies. Family studies demonstrated that the gene responsible for the syndrome was located on chromosome 17, and 20      examination of the p53 gene as a candidate gene revealed that this gene was mutated in five families (Malsin et al, Science 250:1233 (1990)). In the last two years, two genes linked to familial breast cancer, designated BRCA1 and BRCA2, have been 25      isolated and characterized. BRCA1 is at 17q21 (Claus et al, Am. J. Epidemiology 131:961 (1990); Hall et al, Science 250:1684 (1990); Easton et al, Am. J. of Human Genetics 52(4):678 (1993); Black et al, Am. J. of Human Genetics 52(4):702 (1993); Bowcock et al, 30      Am. J. of Human Genetics 52(4):718 (1993); Miki et al, Science 266:66 (1995)). The demonstration of

loss of heterozygosity (LOH) at 17q25 has defined another potential tumor suppressor gene (Lindblom et al, Human Genetics 91:6 (1993); Cornelis et al, Oncogene 8:781 (1993); Theile et al, Oncogene 10:439 (1995)).

The present invention relates at least in part, to a novel gene at 17q25 designated K12. K12 encodes a product that is secreted by cancer cells, for example, breast and ovarian cancer cells. The gene is expressed in these tissues at a level that is at least 100 times higher than that of any other malignant or normal tissue examined. The discovery of the K12 gene makes possible novel tumor detection and treatment methodologies.

15

#### OBJECTS AND SUMMARY OF THE INVENTION

It is a general object of the invention to provide a novel cancer-related protein and nucleic acid sequence encoding same.

It is another object of the invention to provide a method of detecting the presence of neoplastic cells, including breast and ovarian cancer cells, in a biological sample.

It is a further object of the invention to provide a method of treating a neoplastic condition in a mammal in need of such treatment.

It is yet another object of the invention to provide a method of screening compounds for their ability to bind to, or alter the activity of, the K12 gene product.

In one embodiment, the present invention relates to an isolated nucleic acid encoding the K12 protein, or portion thereof of at least 15 consecutive bases, or complement thereof. The invention also relates to 5 a recombinant molecule comprising such a nucleic acid and a vector, and to a host cell comprising same. In addition, the present invention relates to a method of producing the K12 protein, or portion thereof of at least 5 amino acids, comprising culturing the 10 above-described host cells under conditions such that the nucleic acid is expressed and the K12 protein, or portion thereof, is thereby produced.

In a further embodiment, the present invention relates to an isolated nucleic acid consisting 15 essentially of a double-stranded DNA molecule, one strand of which encodes the K12 protein, or portion thereof of at least 15 consecutive base pairs. The invention also relates to a recombinant molecule comprising such a nucleic acid operably linked to and 20 in inverse orientation with respect to a promoter. The invention further relates to a method of inhibiting K12 protein production in a host cell comprising introducing into the cell such a recombinant molecule under conditions such that the 25 nucleic acid is transcribed and production of the K12 protein is thereby inhibited.

In yet another embodiment, the present invention relates to a method of screening a test compound for 30 its ability to bind to or otherwise alter the growth stimulatory activity of the K12 protein. The method comprises comparing the K12 protein activity using a

culture of cells susceptible to the growth stimulatory effects of the K12 protein, in the presence and absence of the test compound. A reduction in the growth of the cells in the presence 5 of the test compound is indicative of a K12 protein inhibitory activity of the test compound, an increase in the growth of the cells being indicative of a K12 protein activating activity of the test compound.

10 Further objects and advantages of the present invention will be clear from the description that follows.

#### BRIEF DESCRIPTION OF THE DRAWINGS

15 Figure 1. Predicted amino acid sequence of the human K12 gene product deduced from the human K12 cDNA sequence. The underlined region is the proposed membrane spanning domain.

Figure 2. Human K12 cDNA sequence. K12 promoter (1-195) and cDNA (196-2180).

Figure 3A-D. K12 expression.

20 Figure 4. Western blot probed with antiserum to K12. Concentrated media from K562 cells transfected with: 1) empty vector, 2) K12 + 7aa flag, 3) K12 with C terminus addition, 4) full length K12, and 5) ZR75-1 cells (not transfected), and 6) molecular weight standards (smallest is 32kDa). Soluble protein extracts from K562 cells transfected with: 7) empty

vector, 8) K12 + 7aa flag, 9) full length K12, and  
10) ZR75-1 cells (not transfected).

Figure 5. Subcellular localization of K12 to the  
Golgi. Same field of view of ZR75-1 cells that were  
5 grown on slides, acetone-fixed and double stained  
with: A, antigen-purified anti-K12 polyclonal  
antibody followed by FITC-conjugated goat anti-rabbit  
IgG secondary antibody and B, rhodamine conjugated  
Wheat Germ Agglutinin (an immunochemical marker for  
10 Golgi bodies).

Figure 6. Immunoperoxidase staining of normal  
breast tissue, A, and colloid breast carcinoma, B,  
with monoclonal antibody 7C3 against K12. C is a  
isotype matched P3 control. Dark brown staining  
15 reflects monoclonal antibody binding to K12 antigen.

Figure 7. Growth curves for K562 cells grown in  
condition media from: KDcmK+( ◆ ), K562 cells  
secreting K12 into the media, or KdcmD+( ■ ), K562  
cells transfected with an empty vector and producing  
20 no detectable K12 in media.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to the mammalian  
K12 gene product and nucleic acid sequence encoding  
same. The K12 gene product is over expressed in  
25 certain cancer cells, including breast and ovarian  
cancer cells, and thus provides a useful marker for

cancer in cytopathology. As the K12 protein is secreted by certain cancers (including breast and ovarian cancers), its presence in, for example, serum, can be used in detecting the presence of 5 neoplastic cells and/or monitoring tumor progress in a mammal. The identification of K12 as a cancer-related gene makes possible new methods of cancer treatment, in addition to new approaches to tumor detection.

10 The present invention relates generally to a nucleic acid sequence encoding a K12 protein, particularly, a mammalian K12 protein, more particularly, human K12 protein, or portion of that encoding sequence. The invention further relates to 15 the encoded protein, polypeptide or peptide. The term "portion", as used herein, and as applied to nucleic acid sequences, refers to fragments of at least 15 bases, preferably, at least 30 bases, more preferably, at least 150 bases and, most preferably, 20 at least 300 or 500 bases. As applied to proteins, the term "portion" relates to peptides and polypeptides of at least 5 amino acids, preferably, at least 10 amino acids, more preferably, at least 25 50 amino acids and most preferably, at least 100 or 240 amino acids. The invention also relates recombinant molecules comprising the above nucleic acid sequences and to host cells transformed therewith. In addition, the invention relates to 30 methods of making the protein, polypeptide or peptide encoded in the nucleic acid sequence by culturing the transformed host cells under appropriate conditions.

Furthermore, the invention relates to methods of screening compounds for the ability to bind to or alter the activity of the K12 gene product. Test compounds can be screened for such abilities, for 5 example, using standard cell culture growth assays and standard binding assays. In addition, the invention relates to cancer detection and treatment methodologies based on the K12 protein and its encoding sequence.

10 K12 Protein, Encoding Sequence, Methods of Production and Anti-K12 Antibodies

The present invention relates to nucleotide sequences that encode the amino acid sequence of the mammalian K12 protein, particularly, the human K12 15 protein, or portions thereof as defined above (eg the extracellular portion, amino acids 1-140). In particular, the present invention relates to nucleotide sequences that encode the amino acid sequence given in Figure 1, or portions thereof as 20 defined above (the DNA sequence given in Figure 2 being only an example). Further, nucleotide sequences to which the invention relates include those encoding substantially the same protein as shown in Figure 1, for example, inter- and 25 intraspecies variations thereof, as well as functional equivalents of the sequence shown in Figure 1. The invention further relates to nucleotide sequences substantially identical to the sequence shown in Figure 2. A "substantially 30 identical" sequence is one the complement of which

hybridizes to the nucleic acid sequence of Figure 2 at 55°C in 3 X saline/sodium citrate (SSC) containing 0.1% SDS and which remains bound when subjected to washing at 55°C with 1 X SSC containing 0.1% SDS

5 (note: 20 X SSC = 3 M sodium chloride/0.3 M sodium citrate). The invention also relates to nucleic acids complementary to those described above.

The present invention also relates to a recombinant molecule comprising a nucleotide sequence 10 as described above and to a host cell transformed therewith. Using standard methodologies, well known in the art, a recombinant molecule comprising a vector and a nucleotide sequence encoding the K12 protein, or portion thereof as defined above, can be 15 constructed. Vectors suitable for use in the present invention include plasmid and viral vectors. Plasmid vectors into which a nucleic sequence encoding the K12 protein, or portion thereof, can be cloned include any vectors compatible with transformation 20 into a selected host cell. Such vectors include SV.NEO and CMV.NEO (eg pcDNA and PC1-neo). The nucleotide sequence of the invention can be present 25 in the vector operably linked to regulatory elements, for example, a promoter. Suitable promoters include, but are not limited to CMV, SV40 and major fat globule protein promoters.

As indicated above, the recombinant molecule of the invention can be constructed so as to be suitable for transforming a host cell. Suitable host cells 30 include prokaryotic cells, such as bacteria, lower eukaryotic cells, such as yeast, and higher

eucaryotic cells, such as mammalian cells, and insect cells. The recombinant molecule of the invention can be introduced into appropriate host cells by one skilled in the art using a variety of known methods.

5 The present invention further relates to a method of producing K12 protein, or portions thereof as defined above. The method comprises culturing the above-described transformed host cells under conditions such that the encoding sequence is  
10 expressed and the protein thereby produced.

The nucleic acid sequence(s) of the invention can be used, in accordance with standard protocols, as probes and primers. As such, portions of the K12 gene sequence can be used.

15 The present invention further relates to the mammalian K12 protein, particularly, the human K12 protein, substantially free of proteins with which it is normally associated, or portions thereof as defined above. The proteins, polypeptides and  
20 peptides of the invention can be produced recombinantly using the nucleic acid sequences as described above, or chemically using known methods. The protein of the invention can be produced alone or as a fusion product, for example, with a protein such  
25 as betagalactosidase. Such fusion products can be produced recombinantly. For example, the coding sequence of the invention (eg the sequence encoding the mammalian K12 protein) can be cloned in frame with a sequence encoding another protein (such as betagalactosidase) and the fusion product expressed  
30 in an appropriate host cell.

The proteins, polypeptides and peptides of the invention can be used as antigens to generate K12 specific antibodies. Methods of antibody generation are well known in the art (see also Example V). Both 5 monoclonal and polyclonal antibodies are included within the scope of the invention, as are binding fragments thereof. The monoclonal antibody 7C3 is preferred. One skilled in the art will appreciate that such antibodies can be used to selectively 10 identify and isolate the K12 protein and portions thereof. In addition, the antibodies can be used *in vivo* or *in vitro* to block activity (eg growth stimulatory activity) of the K12 protein.

#### Compound Screens

15 The present invention also relates to methods of using the proteins of the invention (eg, recombinantly produced K12 protein) to screen compounds for their ability to bind to or alter (eg inhibit) the activity of K12, and thus to identify 20 compounds that can serve, for example, as K12 protein agonists or antagonists. In a one screening assay, the K12 protein, or portion thereof, is incubated with cells susceptible to the growth stimulatory activity of the K12 protein, in the presence and 25 absence of a compound the K12 activity altering or binding potential of which is to be tested. Growth of the cells is then determined. A reduction in cell growth in the test sample indicates that the test compound binds to and thereby inactivates the K12

protein, or otherwise inhibits the K12 protein activity.

Transgenic animals (e.g. rodents) that over express the K12 gene, for example, in mammary or ovarian tissue, can be used to screen compounds <sup>5</sup> *in vivo* for the ability to inhibit development of tumors resulting from the K12 over expression or to treat such tumors once developed. Transgenic animals that have mammary tumors of increased invasive or malignant potential can be used to screen compounds, <sup>10</sup> including antibodies or peptides, for their ability to inhibit the effect of K12. Such animals can be produced, for example, as described in Example VIII.

Screening procedures such as those described <sup>15</sup> above are useful for identifying agents for their potential use in pharmacological intervention strategies in such areas as breast or ovarian cancer treatment.

#### Pharmaceutical Compositions

<sup>20</sup> The present invention also relates to pharmaceutical compositions comprising, as active agent, the proteins, peptides, nucleic acids or antibodies of the invention. The invention also relates to compositions comprising, as active agent, <sup>25</sup> compounds selected using the above-described screening protocols. Such compositions include the active agent in combination with a pharmaceutically acceptable carrier. The amount of active agent in the composition can vary with the agent, the patient <sup>30</sup> and the effect sought. Likewise, the dosing regimen

will vary depending on the composition and the disease/disorder to be treated.

Detection/Diagnosis:

5 The present invention further relates to methods of detecting/diagnosing a neoplastic or preneoplastic condition in a mammal (for example, a human).

10 Examples of conditions that can be detected/diagnosed in accordance with these methods include, but are not limited to ovarian tumors, mammary tumors and prostate cancers.

15 One detection/diagnostic method comprises: (a) obtaining from a mammal (eg a human) a biological sample, (b) detecting the presence in the sample of the K12 protein and (c) comparing the amount of product present with that in a control sample. In accordance with this method, the presence in the sample of elevated levels of the K12 gene product indicates that the subject has a neoplastic or preneoplastic condition.

20 Biological samples suitable for use in this method include biological fluids such as serum, plasma, pleural effusions, urine and CSF. Since the K12 product is a secreted protein, plasma and/or serum samples are preferred. Tissue samples (eg slices) can also be used in the method of the invention, including samples derived from biopsies. Cell cultures or cell extracts derived, for example, from tissue biopsies can also be used, as can cytopsin preparations from pleural effusions.

The detection step of the present method can comprise:

5 i) contacting the biological sample with a compound (eg a protein) that forms a complex with the K12 gene product under conditions such that the complex can form; and

10 ii) determining the amount of complex formed and comparing that amount with a control sample.

(For example, when the biological sample is a pleural effusion, controls can include exudative (eg pneumonia) and non-exudative (eg congestive heart failure) types.)

15 The compound is preferably a binding protein, eg an antibody, polyclonal or monoclonal, or antigen binding fragment thereof. Monoclonal antibody 7C3 is preferred (a hybridoma producing antibody 7C3 was deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD 20852, on November 19, 1996, under the terms of the Budapest 20 Treaty under Accession No. ATCC HB-12238).

25 The compound, which can be labeled with a detectable marker (eg fluorophore, chromophore or isotope, etc). Where appropriate, the compound can be attached to a solid support such as a bead, plate, filter, resin, etc.

30 Determination of formation of the complex can be effected by contacting the complex with a further compound (eg an antibody) that specifically binds to the first compound (or complex). Like the first compound, the further compound can be attached to a

solid support and/or can be labeled with a detectable marker.

The identification of elevated levels of K12 protein in accordance with the present invention makes possible the identification of subjects (patients) that are likely to benefit from adjuvant therapy. For example, a biological sample from a post primary therapy subject (eg subject having undergone surgery) can be screened for the presence of circulating K12 protein, the presence of elevated levels of the protein, determined by studies of normal populations, being indicative of residual tumor tissue. Similarly, tissue from the cut site of a surgically removed tumor can be examined (eg immunofluorescently), the presence of elevated levels of product (relative to the surrounding tissue) being indicative of incomplete removal of the tumor. The ability to identify such subjects makes it possible to tailor therapy to the needs of the particular subject. Subjects undergoing non-surgical therapy, eg chemotherapy or radiation therapy, can also be monitored, the presence in samples from such subjects of elevated levels of K12 protein being indicative of the need for continued treatment. Staging of the disease (for example, for purposes of optimizing treatment regimens) can also be effected, for example, by lymph node biopsy eg. with antibody specific for the K12 protein.

The present invention also relates to a kit that can be used in the detection of K12 protein. The kit can comprise a compound that specifically binds the

K12 protein (eg binding proteins (eg antibodies or binding fragments thereof (eg F(ab')<sub>2</sub> fragments))), for example, disposed within a container means. The kit can further comprise ancillary reagents, including buffers and the like.

5 The diagnostic methodologies described herein are applicable to both humans and non-human mammals.

Therapy:

10 Antisense oligonucleotides complementary to K12 mRNA can be used to selectively diminish or oblate the expression of the protein. More specifically, antisense constructs or antisense oligonucleotides can be used to inhibit the production of K12 in high

15 expressing cancer (e.g., breast or ovarian) cells.

Antisense mRNA can be produced by transfecting into target cancer cells an expression vector with the K12 gene sequence, or portion thereof, oriented in an antisense direction relative to the direction of

20 transcription. Appropriate vectors include viral

vectors, including retroviral vectors, as well as

nonviral vectors. Tissue specific promoters can be

used (eg mammary specific promoters). Alternatively, antisense oligonucleotides can be introduced directly

25 into target cells to achieve the same goal.

Oligonucleotides can be selected/designed to achieve the highest level of specificity and, for example, to bind to K12 mRNA at the initiator ATG.

30 One skilled in the art will appreciate from a reading of this disclosure that monoclonal antibodies to K12 or its receptor can be used to block the

action of K12 and thereby control growth of cancer cells. This can be accomplished by infusion of antibodies that bind to K12 and block its action or antibodies to the receptor for K12.

5 The therapeutic methodologies described herein are applicable to both human and non-human mammals.

Certain aspects of the present invention are described in greater detail in the non-limiting Examples that follow.

10

EXAMPLE I

## Identification and Isolation of K12

A ~500 bp DNA fragment located just upstream of the CD7 HS1 DNase hypersensitive site was used as a probe against an mRNA northern blot and a 1.8 kb transcript was detected in the human erythroleukemic cell line HEL. This 500bp DNA probe was then used to screen a cDNA library made from the human erythroleukemic cell line K562, and subsequently several clones constituting a 1.8 Kbp cDNA were identified, isolated and designated "K12". The sequence of this cDNA, shown in Figure 2, reveals a single long open reading frame of 786 bp that is in the same 5' to 3' orientation as CD7. (Schanberg et al, Proc. Natl. Acad. Sci. USA 88:603 (1991).)

EXAMPLE II

## Expression Patterns of K12

To investigate the range of K12 expression, poly-A+ and total RNAs from many different human cell lines and tissues were analyzed by northern blots probed with radiolabelled K12 cDNA. Northern blots containing 3-4 µg/lane poly-A RNA demonstrate a complete lack of K12 expression in T cell (Jurkat, 5 Hut78, CEM) and B cell (BL2, Ramos) lines, as well as in a megakaryocyte line (Meg-01). A moderately low level of expression was seen in the erythroleukemic cells HEL and K562 (Fig. 3A) and, only after a very long exposure, is K12 mRNA detectable in a colon carcinoma line (HT29) and cervical carcinoma line 10 (HeLa). However, much higher levels are evident in 15 an ovarian cancer (OVCA420) and breast cancer (SKBR3) cell lines (Fig. 3B). A northern blot utilizing 20 µg total RNA/lane for breast cancer lines shows a very high level of K12 RNA accumulation, especially 20 when compared to a lane of poly A+ RNA from K562 cells (Fig. 3D). The first lane contains RNA from K562 cells that are over expressing K12 because it has been transfected with a K12 expression vector. A poly-A+ northern blot (Fig. 3C), demonstrates that 25 K12 is also transcribed in many normal human tissues. This blot shows expression in peripheral blood leukocytes (PBL). The highest level of expression is in granulocytes but expression is seen in monocytes

and some lymphocytes by FACS analysis of permeabilized cells with the 7C3 antibody.

### EXAMPLE III

#### Analysis of the Sequence of the Primary Transcript

5        The cDNA reveals an open reading frame predicting a product of 248 amino acids (Figures 1 and 2). This predicts a final unmodified protein of 27 kD, a size that was confirmed by *in vitro* transcription/translation of K12 RNA. The sequence  
10      of the gene is novel and BLAST analysis reveals short regions (10-15 amino acids) of similarity to members of the immunoglobulin supergene family. The predicted primary sequence (Figure 1) shows two regions of intense hydrophobicity, including a 20  
15      amino acid region near the middle of the molecule, consistent with a membrane spanning domain, and one at the amino terminus, consistent with a leader sequence. The N terminus demonstrates several potential protease cleavage sites as identified near  
20      the transmembrane domain.

### EXAMPLE IV

#### Characterization of the Protein Product

25        A GST-K12 fusion gene was prepared by cloning bases 200-1092 of the K12 cDNA into the cloning site of the PGEX2TK GST fusion vector (Pharmacia). A

55 kDa GST-K12 fusion protein was overexpressed in bacteria, partially purified and injected into rabbits and mice for making both polyclonal and monoclonal antisera. Polyclonal antiserum to K12 was 5 used for western blotting of ZR75-1 protein extracts and a cluster of bands was revealed around 25kDa, likely indicating cleavage of the signal peptide followed by possible modification of the protein. Many cell lines do not reveal a detectable protein, 10 including K562 which expressed the RNA, but at much lower levels than the breast cancer lines. However K562 cells that were stably transfected to overexpress K12 synthesize a protein product of the same size as seen in breast cancer lines. K562 15 transfected with the vector alone did not produce K12 detectable with the monoclonal antibody by Western analysis (Figure 4).

In order to determine the localization of K12 within the cell, breast cancer cells were lysed in 20 100 mM sodium carbonate, pH 11.5. A Western blot of the resulting pellet and supernatant fractions shows that K12 is found in the pellet with other insoluble membrane proteins and further studies show that K12 can be resolubilized in a detergent solution of 1% 25 Triton X-100. These results demonstrate K12 behaves as an integral membrane protein.

30 Immunohistolocalization studies using both fluorescent and light microscopy demonstrated that K12 accumulates in a characteristic perinuclear pattern generally associated with localization to the Golgi bodies (Fig. 5) FACS analysis failed to

demonstrate expression on the surface of the cell, whereas it could be detected in permeabilized cells.

**EXAMPLE V**

5 Demonstration of Expression of K12 in Breast and  
Ovarian Cancer Tissues

The anti-K12 monoclonal antibody, 7C3, was produced by fusing spleen cells from a K12 immunized mouse with an immortalized B-cell line. Individual cell hybrids were screened for reactivity to K12 protein and one clone, 7C3, was identified and cloned (Scearce and Eisenbarth, Production of monoclonal antibodies reacting with the cytoplasm and surface of differentiated cells. Methods in Enzymology, PH Conn (Ed.) vol. 103:459, Academic Press, 1983). The monoclonal antibody was used in immunostaining of acetone fixed normal and malignant breast and ovarian tissues, chosen because of the high level of expression of K12 in breast cancer lines. An isotype matched P3 murine antibody was used as a negative control. All antibodies were conjugated to avidin and the developing system was a biotin horseradish peroxidase. Significant staining occurred only with the 7C3 antibody. Normal glandular elements showed moderate levels of staining with accentuation at the periphery of the glandular tissue (Fig. 6). Stromal tissue demonstrated a low level of general staining typical of molecules in an extracellular location. Breast cancers stained with a higher intensity and

islands of malignant cells could be detected. (Fig. 6).

EXAMPLE VI

Demonstration that K12 is a Secreted Molecule

Because of the localization to the Golgi, it was hypothesized that the molecule may be secreted.

5 Breast cancer cell lines ZR75-1 and MDAR-MB231 were grown in low serum media, and the supernatant was collected and concentrated. Protein aliquots of concentrated cell supernatants were Western blotted and probed with antigen-purified polyclonal antibodies reactive agents K12. A molecule of approximately 20kDa was identified, with several bands of lesser intensity but slightly slower mobility, typical of molecules that are glycosylated or modified (Figure 7).

10 Although K562 cells express K12 at low levels, no secreted product was identified. However, the normal CMV-K12 cDNA transfected into K562 cells produced K12 product in the media. A K12 gene was produced with an inserted 7 amino acid flag that prevented secretion of the protein, although it could be detected within the cells at high levels.

15 Likewise, cells transfected with empty vector did not secrete K12 in the media. In order to optimize the detection of the secreted product, the transfected cells were grown in media containing reduced amounts of calf serum. Reduction of the serum in the media for all three lines revealed significant reduction in

growth rate or survival for all the lines except for those secreting the K12 product. These results indicate a growth regulatory role for the secreted product.

5       Conditioned media was prepared by growing transfected K562 cells in media supplemented with 0.5% fetal calf serum for two days. Cells transfected with CMV-K12 secreted K12 into their media, whereas cells transfected with empty vector 10 did not. The rate of growth of K562 cells grown in this media was determined (Fig. 7). Only the conditioned media from the cells secreting K12 could sustain the growth of K562 cells in low serum concentration media.

15

#### EXAMPLE VII

##### Expression and Characterization of K12 Receptor

Available data indicate that K12 functions as a growth factor produced by breast glandular tissue and 20 breast cancer cells. Target cells for K12 can be determined by identifying the distribution of receptors of K12 and the binding characteristics. To this end, a K12-immunoglobulin recombinant fusion protein can be prepared (Wee et al, Cell Immunol. 25 158:353 (1994)) and a determination made as to the cells to which it binds. K562 erythroleukemia cells can be used since these cells were growth responsive to K12 in the conditioned media studies described above and are likely to express a receptor for K12

protein. K562 cells can be incubated with the fusion protein in either PBS or DMEM (with or without 10 mM EDTA) containing 2% BSA and NaN<sub>3</sub>. After incubation for 30 minutes, the cells can be washed with PBS 5 containing 2% BSA, and fluorescein-conjugated goat anti-human IgG1 can be used as a secondary reagent to examine binding in FACS analysis on a FACStar flow cytometer available in the core Flow Cytometry Laboratory at Duke. Specific binding can be 10 determined by the use of human IgG as a control reagent to determine non-specific binding. The ideal binding conditions related to divalent ion concentration and media conditions can be determined and binding characteristics can be determined by 15 Scatchard analysis using a <sup>125</sup>I labeled K12-Ig fusion molecule (Earp et al, Breast Cancer Research & Treatment 35:115 (1995)).

The receptor that binds K12 can be characterized so as to determine whether it is novel or a 20 previously characterized receptor without a known ligand. The cell lines that have the highest level of binding by K12 can be surface labeled with <sup>125</sup>I as described (Aruffo et al, Proc. Natl. Acad. Sci. USA 89:10242 (1992)) then incubated with the K12-Ig 25 fusion protein for 2 hours in DME/5% FBS. After washing with cold PBS, fusion protein can be cross-linked with cell surface proteins with DTSSP or other cross-linker, such as BASED, BS, or SAED. After 60 minute incubation at 4°C, cells can be washed, lysed 30 with NP-40, PMSF and TLCK (Patel et al, J. Exp. Med. 181:1563 (1995)). Ig complexes can then be purified

with protein A-Sepharose beads. Solubilized complexes can be examined by SDS gel electrophoresis and by autoradiography. These studies will determine the subunit composition of the receptor. If it is a 5 monomer, the encoding gene can be cloned by either genetic or biochemical methods. If the receptor is composed of different subunits, the subunits can be isolated biochemically and the individual components characterized. If the receptor is novel, the gene 10 encoding it can be cloned by either biochemical purification or expression cloning.

#### EXAMPLE VIII

##### Transgenic Animals that Over Express K12

Transgenic mice that overexpress K12 in mammary 15 tissue can be produced as follows. The K12 gene can be linked either to the murine mammary specific promoter for the whey acidic protein (WAP) gene (Leroy et al, Genes, Chromosomes Cancer 6:156 (1993) Sandren et al, Cancer Res. 55:3915 (1995)) or the 20 MMTV promoter (Berard et al, EMBO Journal 13:5570 (1994)) to produce two different transgenic lines (Schanberg et al, J. Immunol. 155:2407 (1995)). An additional mouse line can be produced that utilizes 25 the WAP promoter and a non-secretory variant (non-secretory variants can be produced by the insertion of a 9 amino acid Flag in the amino terminus or leader sequence). The WAP promoter produces high levels of expression in the lactating and pregnant

breast of mice and the MMTV promoter produces a broader range of expression in different tissues and very high levels of expression. The MMTV promoter is more likely to produce embryonic or fetal lethals but 5 may permit determination of the effect of over expression of K12 on different tissues during development. Patterns and levels of K12 expression can be determined and the mammary tissues examined on lines of mice during pregnancy and lactation.

10 Mammary tissue can be examined for the presence of atypia or the development of malignancy.

\* \* \*

All documents cited above are hereby incorporated in their entirety by reference.

15 One skilled in the art will appreciate from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the invention.

WHAT IS CLAIMED IS:

1. An isolated nucleic acid encoding K12 protein.
2. The nucleic acid according to claim 1 wherein said K12 protein is mammalian K12 protein.
3. The nucleic acid according to claim 1 wherein said K12 protein has the amino acid sequence set forth in Figure 1.
4. The nucleic acid according to claim 2 wherein said mammalian K12 protein is human K12 protein.
5. An isolated nucleic acid encoding mammalian K12 protein, or portion thereof of at least 15 consecutive bases, or complement thereof.
6. The nucleic acid according to claim 5 wherein said mammalian K12 protein is human K12 protein.
7. The isolated nucleic acid according to claim 5 wherein the nucleic acid encodes the amino acid sequence set forth in Figure 1, or portion thereof of at least 5 amino acids.
8. The isolated nucleic acid according to claim 7 wherein the nucleic acid has the sequence

shown in Figure 2, or a sequence substantially identical thereto, or portion thereof of at least 15 consecutive bases.

9. The isolated nucleic acid according to claim 8 wherein said nucleic acid has the sequence shown in Figure 2, or portion thereof of at least 15 consecutive bases.

10. The isolated nucleic acid according to claim 9 wherein the nucleic acid has the sequence shown in Figure 2.

11. A recombinant molecule comprising said nucleic acid according to claim 1 and a vector.

12. The recombinant molecule according to claim 11 further comprising a promoter operably linked to said nucleic acid sequence.

13. A host cell comprising said recombinant molecule according to claim 11.

14. A method of producing K12 protein comprising culturing said host cell according to claim 13 under conditions such that said nucleic acid sequence is expressed and said K12 protein is thereby produced.

15. A recombinant molecule comprising the nucleic acid sequence according to claim 5 and a vector.

16. The recombinant molecule according to claim 15 further comprising a promoter operably linked to said nucleic acid sequence.

17. A host cell comprising said recombinant molecule according to claim 15.

18. A method of producing mammalian K12 protein, or portion thereof, comprising culturing said host cell according to claim 17 under conditions such that said nucleic acid sequence is expressed and said mammalian K12 protein, or portion thereof, is thereby produced.

19. An isolated mammalian K12 protein or portion thereof of at least 5 consecutive amino acids.

20. The protein according to claim 19 wherein said protein has the amino acid sequence shown in Figure 1.

21. An antibody specific for the protein, or portion thereof, of claim 19.

22. The antibody according to claim 21 wherein said antibody is 7C3.

23. A method of detecting the presence of neoplastic or preneoplastic cells in a mammal comprising:

- i) obtaining a biological sample from said mammal;
- ii) screening said sample for an elevated level of K12 protein, relative to a level present in a corresponding normal biological sample,

wherein said elevated level is indicative of the presence of said neoplastic or preneoplastic cells.

24. The method according to claim 23 wherein said sample is a biological fluid.

25. The method according to claim 23 wherein the sample is tissue sample.

26. The method according to claim 23 wherein said screening is effected by contacting said sample with a compound that forms a complex with K12 protein under conditions such that the complex can form; and determining the amount of complex formed.

27. The method of claim 26 wherein said compound is a binding protein.

28. The method according to claim 27 wherein the binding protein is an antibody or binding fragment thereof.

29. A kit for use in the detection of K12 protein comprising a compound that specifically binds to K12 protein disposed within a container means.

30. The kit according to claim 29 wherein said compound is an antibody or binding fragment thereof.

31. A method of treating a neoplastic or preneoplastic condition comprising introducing into a mammal in need of such treatment an antisense construct that comprises a vector and a nucleic acid sequence encoding K12 protein, or portion thereof, oriented in an antisense direction relative to the direction of transcription, under conditions such that sequence is expressed and said treatment thereby effected.

32. A method of screening a compound for its ability to modulate K12 protein growth promoting activity comprising incubating K12 protein, or portion thereof, with cells susceptible to the growth promoting activity of K12 protein, in the presence and absence of said compound, and assaying for an alteration in the growth rate of said cells in the presence of said compound,

a reduction in the growth rate of said cells being indicative of a compound that modulates said growth promoting activity.

1/8

*Fig. 1*

1 MQTCPLAFPG HVSQALGTLL FLAASLSAQN EGWDSPICTE GVSVSWGEN  
51 TVMSCNISNA FSHVNICKLRA HQQESAIIFNE VAPGYFSRDG WQLQVQGGVA  
101 QLVIKGARDS HAGLYMWHLV GHQRNNRQVT LEVSGAEPQS APDTGFWPVP  
151 AVVTAVFILL VALVMFAWYR CRCSQQRREK KFFLLEPQMK VAALRAGAQQ  
201 GLSRASAEW TPDSEPTPRP LALVFKPSPL GALELLSPQP LFPYAADP\*

*Fig. 2A*

K12 promoter (1-195) and cDNA (196-2180) sequence

1 ATT CCT GCT T CCT T TAG CGT GAA CG CGG GT GCG CTC CCG TGAA ATA  
 51 ATAA AATT CAC CGT CAC GCT T GTT GTG AAC G CGGG TGG GTTC CCG AAA ACT TG  
 101 GAGG CTT CCC GTAA ACC CAG CTC CCT CTC ATCT GGG AGG TG GG TCC CCG C  
 151 GC GG GT CC CGC CGC CT CCT CC CT GG CC C CTC CCT CT CGT GT CT TT CATT TT  
 201 CCT GGG GCT C CGGG GCG CGG AGA AGC TGCA TCC CAG AGGA GCG CGT CCAG  
 251 GAG CGG ACC C GGG AGT GT TT CAAG AGC CAG TG AC AAGG AC CAG GGG CCA  
 301 AGT CCC ACCA GCC ATG CAGA CCT GCC CCT GGC ATT CCT GGC AC GTT  
 351 CCC AGG CCT T GGG ACC CTC CT GT TTT GG CT GC CT CCT T GAG TG CT CAG  
 401 AAT GAAG GCT GGG ACAG CCC CAT CTG CACA GAG GGG TAG TCT CT GT GT C  
 451 TT GGG GCG AG AAC ACC GT CA TG C CT GCAA CAT CT CCA AC GC CCT TCT CCC  
 501 AT GT CAAC AT CAAG CTG CGT GCCC AC GGG AGC GC AGG AGC GC CAT CT TCA AT  
 551 GAG GT GG CTC CAG GCT ACT T CT CCG GGG AC GG CT GG CAG C TCC AGG TT CA  
 601 GGG AGG CGT G GC AC AGC TGG TG AT CA AAG G CGCC CGG GAC TCC CAT GCT G  
 651 GG CT GT AC AT GT GG CAC CTC GT GGG AC ACC AGA GAA ATA A CAG AC AAG TC  
 701 ACG CT GG AGG TTT CAG GT GC AGA ACC CAG TCC GCC CCT G AC ACT GGG TT  
 751 CT GG CCT GT G CC AG CGG TGG TCA CT GCT GT GT CT TC AT CCT CTC TT GG TCG CTC  
 801 TGG TC AT GT TT CG C CT GG TAC AGG TGC CGC GT GT TT CCC AGC A CG CC GGG AG  
 851 AAG AAG TT CT TC CT CCT AGA ACC CAG AT G AAG GT CG CAG CC CT CAG AGC  
 901 GGG AGC CC AG CAG GGT GA GC AG AGC CTC CG CT GA ACT G TGG ACC CCA AG  
 951 ACT CCG AGCC CAC CCA AGG CCG CT GGG AC TG GT GT TCAA ACC CT CAC CA  
 1001 CTT GG AGC CC TGG AGC TG CT GT CCCCC CCA ACC CT GT TT CC AT AT GCG  
 1051 CAG ACC CATA GCG CCT GCA AGG CAG AGAG GAC AC AGG AG AGCC AGC CCT  
 1101 GAG TGC CG AC CTT GGG TGG C GGG C CT GGG TCT CTC GGT CC CAC CC GG AGG  
 1151 GC AC AG AC AC CGG CTT GCT T GGC AGG CT GGG GC CT CT GT GT CAC CC ACT CC

*Fig. 2B*

1201 TGGGTGCGTG CAGACCCTTC CCCTCCACCC CCCAGGTCTT CCAAGCTCTG  
1251 CTTCCTCAGT TTCCAAAATG GAACCACCTC ACCTCCGCAG CACCCGACTT  
1301 ACCAGGACGC ATGCCCTCC CTCTGCCCTC ATCAAACCCA CAGACCCGGA  
1351 CTCCCTTTCT GCCACCCCAG GCTGGTCCGG CCCCAGGTGT GGGGTCCGCT  
1401 CTCTCCACTC CCAGGGCTCC GCGCCCAAGT GAGGGGGCCC CTGCCGGAGC  
1451 CTCAGACACA CTGGAGTTCA GGGCTGGGGG GGCCTTGGCA CATACTGTC  
1501 CCTTGGCTAT GAGCAGGCTT TGGGGGCCCT TCCGCGGCAG CCCCGGGGC  
1551 CGAGGTAGGG TCTGGGGGCT TAGAGGCTGG GATGGCTCCT GGCCCCACCG  
1601 CCAGGGGGCA AGCGCAGGCC GGGCTGGGAG GCGGCGGCGG CGGCTCGGGC  
1651 TGGGGGGTCA GGTGGACGCT GCCTCCGGGG CTGGTCGCGC ATCCCTCAGT  
1701 CCCTCGGCCA CCCGGGGTC GCTCCCTCGT GCCCACCGCA CCTGCCGAGC  
1751 CTCTTGGAC CCAGATCTGT TCATGCTTT GTCTCGTCA CTGCCGGGG  
1801 GCCCTTGAT GTCTTCATCT GTATGGGTG GAAAATCAC CGGGAATCCC  
1851 CCTTCAGTTC TTTGAAAAAG TTCCATGACT CGAATATCTG AAATGAAGAA  
1901 AACAAACCGA CTCACAAACC TCCAAGTAGC TCCAAATGCA ATTTTAAAAA  
1951 TGGAAAACAA AAATCTGAAA GAAACGTCTT TAGTGGCTTT AAGCCCCAAA  
2001 ACGTCCCTAA GGCGTCCTCG AGATGAAGAC GGGGGGGAGC CCCAGCCAGG  
2051 TGGAGACCCC GCAGGACGCG GCGGCGCCCG GTGACCGAGG CCTCGCACAG  
2101 CCGGCCGCCCG TGAGGGTCGG GCCGAGCCAG GGTCCAAGAG GGGCGCGTTT  
2151 GTGTCTCGGG TTAAAATAAG GTTCCGTCCG




Fig. 3D




Fig. 3A

Fig. 3B




Fig. 3C



6/8






Fig. 5A

Fig. 5B

7/8



*Fig. 6A*




*Fig. 6B*



*Fig. 6C*

8/8

Fig. 7



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/21517

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07K 14/435; C12N 1/20, 15/63, 21/04; C12P 21/06

US CL : 435/69.1, 252.3, 252.33, 325, 320.1; 530/350; 536/23.1, 23.5

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.1, 252.3, 252.33, 325, 320.1; 530/350; 536/23.1, 23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, STN: Medline, Caplus, Scisearch, Lifesci, Biosis, Embase, WPIDS, Cancerlit

Sequence search of SEQ ID NO's: 1 and 2 in coomercial data bases

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	US 5,589,358 A (P. A. DAWSON) 31 December 1996, see SEQ ID NO's: 2 and 4.	1, 2, 5-7 and 11-19
X	LEE, A. S. The accumulation of three specific proteins related to glucose-regulated proteins in temperature-sensitive hamster cell line K12. <i>J. Cellular Physiology</i> . January 1981, Vol. 106, No. 1, pages 119-125, see abstract.	19
Y	COLE et al. Cloning and expression in <i>Escherichia coli</i> K-12 of the genes for major outer membrane protein OmpA from <i>Shigella dysenteriae</i> , <i>Entrobacter aerogenes</i> and <i>Serratia marcescens</i> . <i>J. Bacteriol.</i> January 1982, Vol. 149, No. 1, pages 145-150, see abstract.	1, 2, 11-14
Y		1 and 11-14

Further documents are listed in the continuation of Box C.

See patent family annex.

Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance		
"E" earlier document published on or after the international filing date	"X"	document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

28 JANUARY 1998

Date of mailing of the international search report

26 FEB 1998

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer  
NASHAAT T. NASHED  
Telephone No. (703) 308-0196

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US97/21517

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-20

**Remark on Protest**

The additional search fees were accompanied by the applicant's protest.



No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/21517

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-20, drawn to isolated nucleic acid encoding K12 protein, vector containing the said DNA, transformed host cell, a method of making the K12 protein utilizing the transformed host cell, and the K12 protein.

Group II, claims 21-30, drawn to antibodies raised against the K12 protein, method of detecting the presence of neoplastic or preneoplastic transformation in mammals and kits.

Group III, claim 31, drawn to a method of treatment of neoplastic or preneoplastic conditions.

Group IV, claim 32, drawn to a method for screening for compounds that modulate the activity of the K12 protein.

The inventions listed as Groups I-IV do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The special technical feature in Group I is the nucleic acid encoding the K12 protein, which is different from the antibodies of Group II and unrelated to the screening method of Group IV. Group I contains one use of the nucleic acid sequence which is making the K12 protein by a recombinant method. Since the method of Group III represents a second use for the DNA, it constitutes a separate Group (37 CFR 1.475(a)). The special technical feature of Group II is the antibodies raised against the K12 protein which is unrelated to the special technical feature of any other group. The special technical feature of the method of Group III is the method of treatment which is different from the screening method of Group IV. Thus, Groups I-IV do not relate to a single inventive concept under PCT Rule 13.1.

